Conflombardia – Europa
Territori d’Europa
Tutti gli articoli
www.ema.europa.eu EMA's Management Board has unanimously approved the renewal of the mandate of the Agency’s Executive Director Emer Cooke, extending her tenure until 30 April 2027.The Board's decision follows the successful completion of the renewal process which was initiated by the...
www.ema.europa.eu Review will assess risk of leukoencephalopathy, a condition affecting the brainEMA’s safety committee (PRAC) has started a review of medicines containing levamisole, authorised in four countries of the European Union (EU) to treat infections caused by parasitic worms in...
www.ema.europa.eu EMA and the Heads of Medicines Agencies (HMA) are warning the public about the growing threat of illegal medicines being advertised and sold online across the European Union (EU).In recent months there has been a sharp rise in the number of illegal medicines marketed as...
www.ema.europa.eu A key initiative for collaboration is EMA’s EU Medicines for all (EU-M4all) programme that enables EMA, in cooperation with the WHO, to support global regulatory capacity building and contribute to the protection and promotion of public health beyond the EU. The latest...
www.ema.europa.eu The European Medicines Agency's (EMA) office is closed from 18:00 on Thursday 14 August 2025 to 08:30 on Monday 18 August 2025.Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600.Please note that this...
www.ema.europa.eu 13 new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended 13 medicines for approval at its July 2025 meeting.The committee recommended granting a marketing authorisation for Aqneursa* (levacetylleucine), for the treatment of Niemann-Pick...